The introduction of ICIs against programmed cell death protein-1 (PD-1) and cytotoxic lymphocyte antigen-4 (CTLA-4) has demonstrated an operative impact on the immune system to counter tumor cells within the TME [3]. This evidence concerns the gene PDCD1 and neoplasm.